LIDOCAINE
Dyskinesia, Drug-Induced
VA Office of Research and DevelopmentSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Dyskinesia, Drug-Induced cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safinamide Zambon SpA | Phase 3 | B |
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)- Novartis Pharmaceuticals | Phase 2 | B |
Amantadine Novartis Pharmaceuticals | Phase 2 | B |
Preladenant Merck Sharp & Dohme LLC | Phase 2 | CCC |
Risperdal University of California, San Diego | Phase 1 | CC |
Seroquel® University of California, San Diego | Phase 1 | CC |
Olanzapine University of California, San Diego | Phase 1 | CC |
Dipraglurant Addex Pharma S.A. | Phase 2/3 | C |
Same molecule, other indications
LIDOCAINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →